A Phase 3 interventional study of Nivolumab and Gemcitabine in Urinary Bladder Neoplasms and Muscle-Invasive Bladder Cancer, sponsored by Bristol-Myers Squibb. Completed at 172 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing nivolumab in Urinary Bladder Neoplasms — 3 open to participants now, 11 under way, none of them phase 3. Nivolumab · Urinary Bladder Neoplasms.
Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, this one is the 2nd largest by enrollment, is one of 6 that started in 2018, is one of 4 in phase 3, and was the 13th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →3 of the 25 studies testing nivolumab in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 15 · Phase 3 4
First in 2015; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 855 is above the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 76 across the 25 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
11 studies in Urinary Bladder Neoplasms by Bristol-Myers Squibb: 1 open now, 1 under way, 1 of them phase 3. Of 10 finished, 3 (30%) have results posted.
Among the 11 studies in Urinary Bladder Neoplasms by Bristol-Myers Squibb, this one has the largest enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 6th registered.
Bristol-Myers Squibb’s Urinary Bladder Neoplasms studies by the year they started, since 2005.
4 of the studies testing nivolumab in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06237920The Netherlands Cancer InstituteStage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | 2026-12-01 |
| NCT03520491Memorial Sloan Kettering Cancer CenterA Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | 2027-01 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
| NCT02496208National Cancer Institute (NCI)Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 11 in Urinary Bladder Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Gemcitabine · Drug: Cisplatin
Biological: Nivolumab · Drug: Gemcitabine · Drug: Cisplatin
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Specified dose on specified days
Also known as: Chemotherapy
Specified dose on specified days
Also known as: Chemotherapy
Pathological Complete Response (pCR) rate, in all randomized participants
Arm B vs. Arm A
Time frame: Approximately 43 months
Event-Free Survival (EFS), in all randomized participants
Arm B vs. Arm A
Time frame: Approximately 36 months
Overall Survival (OS) in all randomized participants
Arm B vs. Arm A
Time frame: Approximately 60 months
Incidence of Adverse Events (AE) in participants who received at least one treatment dose
Time frame: Approximately 60 months
Incidence of Serious Adverse Events (SAE) in participants who received at least one treatment dose
Time frame: Approximately 60 months
Incidence of deaths in participants who received at least one treatment dose
Time frame: Approximately 60 months
Incidence of laboratory abnormalities in participants who received at least one treatment dose
Time frame: Approximately 60 months
pCR rate, descriptively in all concurrently randomized participants
Arm C vs. Arm B and Arm A
Time frame: Approximately 43 months
EFS, descriptively in all concurrently randomized participants
Arm C vs. Arm B and Arm A
Time frame: Approximately 36 months
OS, descriptively in all concurrently randomized participants
Arm C vs. Arm B and Arm A
Time frame: Approximately 60 months
Showing the first 100 of 172 sites across 28 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Nov 2018 to primary completion in Feb 2026, 87 months.
Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 87 months is above that.
Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab